# Psychoactive Drug Screening (PDSP)

> **NIH NIH N01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $3,496,672

## Abstract

The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for
potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders,
and as positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional
magnetic resonance imaging (fMRI) ligands for functional brain imaging.
This program is primarily intended as a screen for compounds that have previously been shown to possess
pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random
screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds). However,
screening maybe conducted on small libraries of synthetic or natural product compounds of unknown activity and on
hit or lead compounds generated through NIH-funded high throughput screening (HTS) or chemistry programs.

## Key facts

- **NIH application ID:** 10209927
- **Project number:** 271201800023C-P00002-9999-1
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** BRYAN ROTH
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,496,672
- **Award type:** —
- **Project period:** 2020-08-30 → 2021-08-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10209927

## Citation

> US National Institutes of Health, RePORTER application 10209927, Psychoactive Drug Screening (PDSP) (271201800023C-P00002-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10209927. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*